



## Alejandro's Story

Alejandro participated in a preemptive DNA sequencing study, called Tapestry, to contribute to medical research. He never imagined

that his genetic test findings would save his life.

His genetic test results revealed a mutation on his PMS2 gene, known to cause Lynch syndrome. This is an inherited condition that raises a person's lifetime risk of developing colon, uterine, stomach, small bowel, kidney and other cancers.

Alejandro's team of genetic counselors and physicians moved quickly to schedule a colonoscopy — which found a 30-millimeter cancerous tumor in his colon. Within weeks of his diagnosis, Alejandro underwent surgery to have the tumor removed, and he will undergo regular screenings in the future.



If I had not received genetic testing, at some point, I would have noticed symptoms. But by then, it probably would have been too late.

**ALEJANDRO MIRAZO**  
Mayo Clinic Patient



### RESEARCHERS PERSPECTIVE

*“More than half of the patients who develop cancer due to inherited mutations are being missed, and that has major implications for family members. We can target prevention strategies for those high-risk individuals and hopefully prevent cancer altogether in future generations of their family.”*

**NILOY JEWEL SAMADDER, MD**  
Mayo Clinic

## Illuminating the Path to Early Detection


*In our partnership with Mayo Clinic we're funding the initiative to expand the Tapestry Project — a multi-cancer early detection testing for patients.*

**The Tapestry Project:** Tapestry recognizes the potential of novel genomic technology in identifying cancers early through the analysis of blood samples. This breakthrough will revolutionize cancer treatment, enhancing survival rates for countless individuals. With over 60,000 participants, the Tapestry Program study at Mayo Clinic is poised to

become a pivotal part of a larger NIH study, taking us closer to a future where cancer is detected early and defeated.

A MAYO CLINIC STUDY FOUND  
**1 in 8 Patients with Cancer**  
HARBOR INHERITED GENETIC MUTATIONS

Your support isn't just an investment; it's a lifeline to those battling cancer.




DESERT MOUNTAIN  
**CARE TOUCHES LIVES**

Funding Innovative World-Class Cancer Research

**Dedicated to Advancing Cancer Research, Prevention, Early Detection, and Targeted Therapies**

## OUR ENDURING VISION

More than 1.2 million Americans develop cancer each year. A new cancer is diagnosed every 30 seconds in the United States. Desert Mountain CARE has remained steadfast, throughout our 26-year history, in our commitment to enhancing the quality of life for those fighting cancer. We've ignited a flame within our community by supporting groundbreaking cancer research and pioneering treatment initiatives at world-class institutions right here in Arizona. CARE supported projects have not only touched the lives of our loved ones but have also contributed to the betterment of humanity.



## INNOVATIVE CANCER RESEARCH



The Desert Mountain community, in partnership with CARE, has invested over \$10 million in funding towards cutting-edge cancer research and treatment initiatives. Your philanthropy has fueled physician-scientists at HonorHealth Research Institute (HHRI) and Mayo Clinic, who are seeing lives saved through remarkable strides in advancing cancer care.

## TOGETHER, WE MAKE A DIFFERENCE!

CARE remains focused on funding projects on prevention, early detection, and precision targeted therapies. Thanks to relentless efforts dedicated to uncovering root causes, implementing preventive measures, advancing genetic detection methods, and pioneering innovative treatments. Physicians are achieving survival and cure rates that would have seemed unimaginable merely a generation ago.



## CANCER IS PERSONAL

*Just as every cancer diagnosis is unique, so too are the stories of the individuals fighting the disease. These testimonials speak to how research CARE has funded is transforming patient lives...*

### HONORHEALTH®

Research Institute

### Judy's Story

"About two years ago, I woke up completely blind in one eye," Judy recalls. Her journey with

Uveal Melanoma took an unexpected turn when her dedicated team of oncologists at HonorHealth sprang into action. Within weeks of her diagnosis, Judy underwent a life-altering surgery to remove her eye. Unfortunately, it was during this challenging time that Judy also learned that her cancer had spread to her liver.

However, hope wasn't lost for Judy. She was offered a unique opportunity to participate in a clinical trial aimed at injecting the tumor to help destroy it—a groundbreaking project supported by Desert Mountain CARE. Today, Judy is thriving.



Keep up the good work. It will help many more people. Charitable giving funds scientists to go further into their studies. Your generosity gives hope. Hope is the future and everybody needs hope.

**JUDY PROBSTFIELD**  
HonorHealth Patient



### RESEARCHERS PERSPECTIVE

*"Advances against [rare cancers] cannot be made until someone makes them a priority. Powered by generosity, we are transforming and saving lives of patients who typically have had little—if any—hope."*

**MICHAEL S. GORDON, MD**  
Chief Medical Officer, HonorHealth Research Institute

## Pioneering Rare Cancer Solutions

At HHRI, researchers are relentlessly pursuing solutions to rare cancers. Currently, we're channeling our resources into two extraordinary projects:

**Tenosynovial Giant Cell Tumor Study (TGCT):** TGCT is a rare cancerous proliferation of the synovium lining joints. HHRI has made a groundbreaking discovery—a "simple" diagnostic

test that eliminates the need for surgery and biopsy, reducing patients' risk and enhancing their quality of life.

**Uveal Melanoma Study (UM):** UM is a rare cancer affecting the eye's choroidal body. HHRI is dedicated to identifying novel biomarkers for the disease, revolutionizing monitoring, and diagnosis.